This poster, presented at MDA 2024, explores the use of ataluren to prevent ambulatory decline in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
This poster, presented at MDA 2024, provides insights into the demographics of young patients with Duchenne muscular dystrophy (DMD) who are receiving deflazacort in the US
This poster presentation, as part of WMS 2023, explores the effects of ataluren on muscle function in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) across 3 clinical trials
This poster presentation, given as part of WMS 2023, explores the effect of ataluren on age at loss of ambulation vs standard of care (SoC) alone on patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
This poster presentation, developed as part of WMS 2023, explores data from the STRIDE Registry and CINRG Natural History Study to assess the effect of mutation-specific treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) on pulmonary function
This poster presentation, given as part of WMS 2023, explores the safety data of ataluren in patients with nonsense mutation Duchenne muscular dystrophy and a variety of characteristics
This poster, presented at WMS 2023, explores the effects of ataluren on muscle function in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) across 3 clinical trials
This poster, presented at WMS 2023, explores the effect of ataluren and standard of care (SoC) receival on age at loss of ambulation in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) vs SoC alone
This poster, presented at WMS 2023, provides results of a propensity score-matched registry analysis, using data from the STRIDE Registry and CINRG Natural History Study, to assess the effect of mutation-specific treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) on pulmonary function
This poster, presented at WMS 2023, explores the safety data and demographics of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) after receiving ataluren
The PTC Therapeutics ‘Connecting the dots’ symposium at WMS 2023 provided an overview of the latest clinical and real-world evidence in nonsense mutation Duchenne muscular dystrophy (nmDMD), and highlighted the importance of continuity in all-around care. This infographic from the symposium summarizes the key evidence presented
This symposium, presented at WMS 2023, provides an overview of clinical trial and real-world data for nonsense mutation Duchenne muscular dystrophy (nmDMD) and examines the importance of all-around care for DMD
This oral presentation at AAN 2023 explored the use of 3 corticosteroids in a Duchenne muscular dystrophy (DMD) mouse model. The study monitored pharmacokinetics and biodistribution, the efficacy on muscle function and damage, and explored potential side effects
This AAN 2023 oral presentation focused on ataluren use for the treatment of nonsense mutation Duchene muscular dystrophy (nmDMD) patients. The symposium detailed the efficacy and safety profile of ataluren in Study 041
The PTC Therapeutics symposium at MDA 2023 focused on all-around care for Duchenne muscular dystrophy (DMD). This symposium detailed how corticosteroids can be integrated into all-around DMD care
The PTC Therapeutics symposium at MDA 2023 focused on all-around care for Duchenne muscular dystrophy (DMD). This infographic, distributed during the symposium, provides a summary of how corticosteroids can be integrated into all-around DMD care
This poster, presented at MDA 2023, provides an overview of a phase 3 placebo-controlled trial assessing the motor function of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) treated with ataluren
This poster, presented at MDA 2023, assesses the efficacy of ataluren on muscle function in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) over 3 trials
This poster, presented at MDA 2023, provides an overview of a phase 3 trial assessing the effects of ataluren on muscle burst activity in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
Year
Therapy area
Congress
Type
Topic
Access PTC abstracts, infographics, posters and symposia presented at international meetings in the fields of pediatric neurology, cognitive neuroscience and movement disorders, such as the Muscular Dystrophy Association (MDA) Annual Clinical & Scientific Conference, the Child Neurological Society (CNS) Annual Meeting, the World Muscle Society (WMS) Annual Congress, and the European Paediatric Neurology Society (EPNS) Congress.